

Procurement of cytostatics in the Republic of Srpska



Djurdjica Kopanja* ^{1,2}, Mira Zrilic ³, Tatjana Kundakovic⁴



¹ Faculty of Medicine, Mega Trade System², Banja Luka, Bosnia-Herzegovina

³ Health Insurance Fund of Republika Srpska (HIF RS), Banja Luka, Bosnia-Herzegovina

⁴ Faculty of Pharmacy, Belgrade, Serbia



Results



Background

- In 2017, there were 36 543 patients with cancer in the hospitals in Republic of Srpska (RS).
- The trend for the growth of diseased patients of younger age is evident.
- The costs for cytostatics in 2017 year amounted to 14,31 millions EUR.
- Procurement of cytostatics at the tertiary level of healthcare is provided through the Health Insurance Fund of Republic of Srpska and has been conducted through public procurement.
- Very often there are the shortages of cytostatics in the hospitals.
- The patients are forced to take over the procurement of these drugs themselves.
- Patients are forced to buy drugs in other countries.

Aims

- To establish the reasons for shortage of cytostatics in the hospitals.
- Examine which cytostatics are most commonly in the shortages.

Methods

- Analysis of public procurement of cytostatics through the HIF in the period from January 2018 to March 2019.

- The HIF of the RS fully finances the procurement of about 120 cytostatics .
- Cytostatics, financed by the HIF RS, are often not marketing authorized in the Bosnia and Herzegovina.
- The procedures for interventional import of drugs are often complicated and long.
- In the RS, for 22 cytostatics (26%) of 84 existing cytostatics on the list, in the February 2019 the HIF was forced to renew the procurement procedure.
- There were not any interested suppliers for the most of medicins.
- BIH market is small and unattractive for many manufacturers of drugs.
- Suppliers offered unrealistically high price.
- Drugs that cannot be provided are, for example, granisetron, melphalan, thioguanine, procarbazine, cladribine, oxaliplatin etc. (Picture 1.)

Поништава се поступак јавне набавке цитотоксичних лијекова у отвореном поступку број: 07/015-3874/18 и то

за лотове за које није пристигла нити једна понуда, у складу са чланом 69. став (2) под а) Закона о јавним набавкама.

5	A04AA02	гранисетрон	концентрат за раствор за ињекцију или инфузију	3 mg
6	A04AA02	гранисетрон	филм-таблете	1 mg
12	L01AA01	циклофосфамид	таблете	50 mg
13	L01AA03	мелфалан	таблете	2 mg
18	L01BB02	меркаптопурин	таблете	50 mg
19	L01BB04	кладрибин	концентрат за раствор за инфузију/раствор за ињекцију	10 mg
20	L01BB05	флуларабин	прашак за раствор за ињекцију или инфузију/ концентрат за раствор за ињекцију или инфузију/ раствор за ињекцију	50 mg
21	L01BB05	флуларабин	таблете	10 mg
27	L01CA04	винорелбин	концентрат за раствор за инфузију	50 mg
28	L01DA01	дактиномицин	прашак за раствор за ињекцију	500 mcg
35	L01XX17	топотекан	концентрат за раствор за инфузију/ прашак за концентрат за раствор за инфузију	1 mg
40	L03AB04	интерферон алфа-2а	раствор за ињекцију	6 M i.j./ml; 0,5ml
41	L03AB04	интерферон алфа-2а	раствор за ињекцију	12M i.j./ml; 0,5ml
43	M05BA06	ибандронска киселина	раствор за ињекцију/концентрат за раствор за инфузију	6 mg

Picture 1. Some of the cytostatics that nobody in the tender offered

Conclusion

- ✓ Propose an amendment to the Public Procurement Law for Medicines to avoid obvious problems and increase the availability of the medicines for cancer patients.

